Outcomes in Asymptomatic Patients Undergoing Coronary Revascularization Before Liver Transplantation

Goyal Umadat1, Jennifer Lee2, Jordan C Ray1

  • 1Division of Cardiovascular Diseases, Mayo Clinic Florida, Jacksonville, FL 32224, USA.

PubMed

Insights

Pre-transplant percutaneous coronary intervention (PCI) did not reduce major adverse cardiovascular events (MACE) in asymptomatic liver transplant (LT) candidates with severe coronary artery disease (CAD). Outcomes were similar whether patients received PCI or medical management before LT.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Interventional Cardiology

Background:

  • Coronary artery disease (CAD) is prevalent in liver transplantation (LT) candidates.
  • The benefit of pre-transplant percutaneous coronary intervention (PCI) on post-LT outcomes is unclear.

Purpose of the Study:

  • To evaluate if pre-transplant PCI improves major adverse cardiovascular events (MACE) in asymptomatic LT candidates with severe CAD.

Main Methods:

  • Single-center cohort study of 111 asymptomatic LT candidates with severe CAD (2005-2025).
  • Compared outcomes between patients who underwent PCI (n=66) and those managed medically (n=45).
  • Primary endpoint: MACE (myocardial infarction, stroke, new systolic dysfunction, post-LT revascularization, all-cause death).

Main Results:

  • No significant difference in composite MACE between PCI and non-PCI groups (52% vs. 60%, p=0.40).
  • PCI was not associated with MACE in Fine-Gray modeling.
  • Independent predictors of MACE included prior myocardial infarction and pre-transplant dialysis.

Conclusions:

  • Pre-transplant PCI is not associated with reduced post-LT MACE in asymptomatic LT candidates with severe CAD.
  • Management decisions should consider other risk factors like prior MI and dialysis status.